Johnson & Johnson secures EC approval for AKEEGA® as the first precision-medicine combo for BRCA1/2-mutated metastatic hormone-sensitive prostate cancer, supported by landmark rPFS data from the AMPLITUDE trial.
AbbVie reports promising Phase 1 MAD results for ABBV-295, a once-weekly injectable amylin analog showing meaningful weight loss and strong tolerability positioning it as a differentiated entrant in the growing cardiometabolic obesity pipeline.
Pfizer’s investigational trispecific antibody, tilrekimig, met its primary endpoint in a Phase 2 study for atopic dermatitis, showing significant skin clearance and a favorable safety profile.
In a major industry shift, Hims & Hers will ditch compounded GLP-1s to offer branded Wegovy and Ozempic at self-pay prices following a settlement with Novo Nordisk.
Roche’s Phase III ALLEGORY trial reveals that Gazyva plus standard therapy helped 76.7% of SLE patients achieve significant clinical improvement. New data published in NEJM highlights Gazyva’s potential to redefine the standard of care in lupus by preventing organ damage and reducing steroid dependency.
Roche’s investigational amylin analog, petrelintide, achieved a statistically significant 10.7% mean body weight reduction in a Phase II trial, offering a well-tolerated alternative to current obesity treatments.
Johnson & Johnson announced FDA approval of TECVAYLI plus DARZALEX FASPRO for relapsed/refractory multiple myeloma with unprecedented clinical data demonstrating significant improvements in progression-free survival and overall survival.
Lilly Employer Connect launches with over fifteen administrators to close the U.S. obesity care gap, offering Zepbound® at a discounted price of $449 for employers looking to expand health benefits and reduce employee out-of-pocket costs.
Johnson & Johnson announces FDA Fast Track designation for nipocalimab in systemic lupus erythematosus. The immunoselective therapy demonstrated reduction in lupus disease activity in Phase 2 JASMINE study, offering potential steroid-sparing benefits and accelerated FDA review timeline.
GSK plc announced on March 3, 2026, the completion of its previously announced GSK RAPT Therapeutics acquisition for approximately $2.2 billion, bringing a California-based clinical-stage biopharmaceutical company specializing in novel therapies for inflammatory and immunologic diseases into its portfolio.
